Defunct Company
Total Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
349
NCT03560479
A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer
Phase: Phase 1/2
Role: Lead Sponsor
Start: May 21, 2018
Completion: Dec 31, 2023
NCT05239221
AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism
Role: Collaborator
Start: Sep 7, 2020
Completion: Aug 23, 2022
NCT05778071
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
Phase: Phase 3
Start: Jun 7, 2023
Completion: Jun 16, 2027